Recap: HOOKIPA Pharma Q2 Earnings

Shares of HOOKIPA Pharma HOOK moved higher by 2.8% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 55.56% year over year to ($0.28), which beat the estimate of ($0.47).

Revenue of $6,685,000 up by 65.02% year over year, which beat the estimate of $3,490,000.

Outlook

HOOKIPA Pharma hasn't issued any earnings guidance for the time being.

HOOKIPA Pharma hasn't issued any revenue guidance for the time being.

Recent Stock Performance

Company's 52-week high was at $14.37

Company's 52-week low was at $5.80

Price action over last quarter: Up 16.72%

Company Overview

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.